U.S. Purchases 600K Doses of New Antibody Treatment Amid Omicron Surge

The United States purchased over 600,000 doses of a monoclonal antibody treatment from Glaxosmithkline and Vir Biotechnology, bringing the total worldwide doses purchased to 1.7 million. This comes as the country attempts to ramp up treatment options as cases of the omicron variant continue to surge. Dr. Asha Shah, Director of Infectious Diseases at Stamford Health joined Cheddar's Opening Bell to discuss.